Fecal immunochemical test accuracy in average-risk colorectal cancer screening

World Journal of Gastroenterology

Volumn 20, Issue 4, 2014, Pages 1038-1047

  Hernandez, Vicent ^a   Cubiella, Joaquin ^b   Gonzalez Mao, M Carmen ^a   Iglesias, Felipe ^a   Rivera, Concepción ^b   Iglesias, M Begoña ^a   Cid, Lucía ^a   Castro, Ines ^b   de Castro, Luisa ^a   Vega, Pablo ^b   Hermo, Jose Antonio ^a   Macenlle, Ramiro ^b   Martínez Turnes, Alfonso ^a   Martínez Ares, David ^a   Estevez, Pamela ^a   Cid, Estela ^b   Vidal, M Carmen ^a   López Martínez, Angeles ^a   Hijona, Elisabeth ^c   Herreros Villanueva, Marta ^c   Bujanda, Luis ^c   Rodriguez Prada, Jose Ignacio ^a   more..

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b Instituto de Investigación Biomédica Ourense Vigo Pontevedra   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

Author keywords

Adenoma; Colorectal neoplasms; Cost benefit analysis; Early detection of cancer; Occult blood; Sensitivity and specificity

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMORBIDITY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; FECES ANALYSIS; FEMALE; HISTOLOGY; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY;

ADENOMA; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FECES; HEALTH CARE COSTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SPAIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84892984102     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i4.1038     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
2. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-1549 [PMID: 18479499 DOI: 10.1111/j.1572-0241.2008.01875.x]
3. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, Church TR. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013; 369: 1106-1114 [PMID: 24047060 DOI: 10.1056/NEJMoa1300720]
4. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J; UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624-1633 [PMID: 20430429 DOI: 10.1016/S0140-6736(10)60551-X]
5. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366: 2345-2357 [PMID: 22612596 DOI: 10.1056/NEJMoa1114635]
6. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev 2011; 33: 88-100 [PMID: 21633092 DOI: 10.1093/epirev/mxr004]
7. Quintero E. Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening? Gastroenterol Hepatol 2009; 32: 565-576 [PMID: 19577340 DOI: 10.1016/j.gastrohep.2009.01.179]
8. Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 2006; 107: 2152-2159 [PMID: 16998938 DOI: 10.1002/cncr.22230]
9. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S, Tichet J, Launoy G. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56: 210-214 [PMID: 16891354 DOI: 10.1136/gut.2006.101428]
10. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF, Selby JV. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1462-1470 [PMID: 17895475 DOI: 10.1093/jnci/djm150]
11. Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Niv Y. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther 2009; 29: 450-457 [PMID: 19035980 DOI: 10.1111/j.1365-2036.2008.03898.x]
12. Parra-Blanco A, Gimeno-García AZ, Quintero E, Nicolás D, Moreno SG, Jiménez A, Hernández-Guerra M, Carrillo-Palau M, Eishi Y, López-Bastida J. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 2010; 45: 703-712 [PMID: 20157748 DOI: 10.1007/s00535-010-0214-8]
13. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, Han DS. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105: 2017-2025 [PMID: 20502450 DOI: 10.1038/ajg.2010.179]
14. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 162-169 [PMID: 19189905 DOI: 10.7326/0003-4819-150-3-200902030-00005]
15. Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 2010; 105: 682-690 [PMID: 19953091 DOI: 10.1038/ajg.2009.668]
16. de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AH, Stegeman I, Kraaijenhagen RA, Fockens P, van Leerdam ME, Dekker E, Kuipers EJ. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol 2012; 107: 1570-1578 [PMID: 22850431 DOI: 10.1038/ajg.2012.249]
17. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697-706 [PMID: 22356323 DOI: 10.1056/NEJMoa1108895]
18. Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, Niv Y. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005; 100: 2519-2525 [PMID: 16279909 DOI: 10.1111/j.1572-0241.2005.00231.x]
19. Jover R, Herráiz M, Alarcón O, Brullet E, Bujanda L, Bustamante M, Campo R, Carreño R, Castells A, Cubiella J, García-Iglesias P, Hervás AJ, Menchén P, Ono A, Panadés A, Parra-Blanco A, Pellisé M, Ponce M, Quintero E, Reñé JM, Sánchez del Río A, Seoane A, Serradesanferm A, Soriano Izquierdo A, Vázquez Sequeiros E. Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy 2012; 44: 444-451 [PMID: 22438159 DOI: 10.1055/s-0032-1306690]
20. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425 [PMID: 15467030 DOI: 10.1093/jnci/djh275]
21. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-428 [PMID: 16083699 DOI: 10.1053/j.gastro.2005.05.056]
22. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146: 244-255 [PMID: 17310048 DOI: 10.7326/0003-4819-146-4-200702200-00003]
23. Greenberg PD, Bertario L, Gnauck R, Kronborg O, Hardcastle JD, Epstein MS, Sadowski D, Sudduth R, Zuckerman GR, Rockey DC. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000; 95: 1331-1338 [PMID: 10811348 DOI: 10.1111/j.1572-0241.2000.02032.x]
24. Strul H, Kariv R, Leshno M, Halak A, Jakubowicz M, Santo M, Umansky M, Shirin H, Degani Y, Revivo M, Halpern Z, Arber N. The prevalence rate and anatomic location of colorectal adenoma and cancer detected by colonoscopy in average-risk individuals aged 40-80 years. Am J Gastroenterol 2006; 101: 255-262 [PMID: 16454827 DOI: 10.1111/j.1572-0241.2006.00430.x]
25. Terhaar Sive Droste JS, Craanen ME, van der Hulst RW, Bartelsman JF, Bezemer DP, Cappendijk KR, Meijer GA, Morsink LM, Snel P, Tuynman HA, van Wanrooy RL, Wesdorp EI, Mulder CJ. Colonoscopic yield of colorectal neoplasia in daily clinical practice. World J Gastroenterol 2009; 15: 1085-1092 [PMID: 19266601 DOI: 10.3748/wjg.15.1085]
26. Betés Ibáñez M, Muñoz-Navas MA, Duque JM, Angós R, Macías E, Súbtil JC, Herraiz M, de la Riva S, Delgado-Rodríguez M, Martínez-Gonzélez MA. Diagnostic value of distal colonic polyps for prediction of advanced proximal neoplasia in an average-risk population undergoing screening colonoscopy. Gastrointest Endosc 2004; 59: 634-641 [PMID: 15114305 DOI: 10.1016/S0016-5107(04)00155-5]
27. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-168 [PMID: 10900274 DOI: 10.1056/NEJM200007203430301]
28. Ladabaum U, Ferrandez A, Lanas A. Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy. Cancer Epidemiol Biomarkers Prev 2010; 19: 2765-2776 [PMID: 20810603 DOI: 10.1158/1055-9965.EPI-10-0530]
29. Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004; 8: iii, 1-234 [PMID: 15193208 DOI: 10.3310/hta8250]
30. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003; 326: 41-44 [PMID: 12511463 DOI: 10.1136/bmj.326.7379.41]
31. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-349 [PMID: 18313558 DOI: 10.1016/j.jclinepi.2007.11.008]
32. Trajman A, Luiz RR. McNemar chi2 test revisited: comparing sensitivity and specificity of diagnostic examinations. Scand J Clin Lab Invest 2008; 68: 77-80 [PMID: 18224558 DOI: 10.1080/00365510701666031]
33. Rozen P, Comaneshter D, Levi Z, Hazazi R, Vilkin A, Maoz E, Birkenfeld S, Niv Y. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010; 116: 2115-2125 [PMID: 20186820 DOI: 10.1002/cncr.25012]
34. Oort FA, van Turenhout ST, Coupé VM, van der Hulst RW, Wesdorp EI, Terhaar sive Droste JS, Larbi IB, Kanis SL, van Hengel E, Bouman AA, Meijer GA, Mulder CJ. Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study. BMC Cancer 2011; 11: 434 [PMID: 21985604 DOI: 10.1186/1471-2407-11-434]
35. Nakama H, Yamamoto M, Kamijo N, Li T, Wei N, Fattah AS, Zhang B. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1995; 46: 228-231 [PMID: 10228797]
36. Nakama H, Zhang B, Fattah AS. A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer. Eur J Cancer 2000; 36: 647-650 [PMID: 10738130 DOI: 0959-8049/00/S]
37. Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer 2001; 37: 398-401 [PMID: 11239763 DOI: 0959-8049/01/S]
38. Salas D. Situacion de los programas de cribado de cáncer colorrectal en España-2012. Available from: URL: http://www.programascancerdemama.org/index.php/situacionde-los-programas-de-cribado-de-cancer-colorrectal-enespana-ano-2012. Accessed March 25, 2013
39. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, Launoy G. Performance of immunochemical faecal occult blood test in colorectal cancer screening in averagerisk population according to positivity threshold and number of samples. Int J Cancer 2009; 125: 1127-1133 [PMID: 19431212 DOI: 10.1002/ijc.24407]
40. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, Bortoli A, Castiglione G, Cazzola L, Confortini M, Mantellini P, Rubeca T, Zappa M. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009; 100: 259-265 [PMID: 19142185 DOI: 10.1038/sj.bjc.6604864]
41. van Roon AH, Wilschut JA, Hol L, van Ballegooijen M, Reijerink JC, 't Mannetje H, Kranenburg LJ, Biermann K, van Vuuren AJ, Francke J, van der Togt AC, Habbema DJ, van Leerdam ME, Kuipers EJ. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 2011; 9: 333-339 [PMID: 21185397 DOI: 10.1016/j.cgh.2010.12.012]
42. Guittet L, Bouvier V, Guillaume E, Levillain R, Ruiz A, Lantieri O, Launoy G. Colorectal cancer screening: why immunochemical faecal occult blood test performs as well with either one or two samples. Dig Liver Dis 2012; 44: 694-699 [PMID: 22525156 DOI: 10.1016/j.dld.2012.03.005]
43. Faivre J, Dancourt V, Manfredi S, Denis B, Durand G, Gendre I, Bidan JM, Jard C, Levillain R, Jung S, Viguier J, Dorval E. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme. Dig Liver Dis 2012; 44: 700-704 [PMID: 22542582 DOI: 10.1016/j.dld.2012.03.015]
44. Castiglione G, Zappa M, Grazzini G, Sani C, Mazzotta A, Mantellini P, Ciatto S. Cost analysis in a population based screening programme for colorectal cancer: comparison of immunochemical and guaiac faecal occult blood testing. J Med Screen 1997; 4: 142-146 [PMID: 9368871 DOI: 10.1177/09 6914139700400306]
45. Grazzini G, Ciatto S, Cislaghi C, Castiglione G, Falcone M, Mantellini P, Zappa M. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence. J Med Screen 2008; 15: 175-181 [PMID: 19106257 DOI: 10.1258/jms.2008.008032]
46. Berchi C, Guittet L, Bouvier V, Launoy G. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. Int J Technol Assess Health Care 2010; 26: 48-53 [PMID: 20059780 DOI: 10.1017/S0266462309990808]
47. Wilschut JA, Habbema JD, van Leerdam ME, Hol L, Lansdorp-Vogelaar I, Kuipers EJ, van Ballegooijen M. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst 2011; 103: 1741-1751 [PMID: 22076285 DOI: 10.1093/jnci/djr385]
48. Wilschut JA, Hol L, Dekker E, Jansen JB, Van Leerdam ME, Lansdorp-Vogelaar I, Kuipers EJ, Habbema JD, Van Ballegooijen M. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011; 141: 1648-1655. e1 [PMID: 21784045 DOI: 10.1053/j.gastro.2011.07.020]
49. Goede SL, van Roon AH, Reijerink JC, van Vuuren AJ, Lansdorp-Vogelaar I, Habbema JD, Kuipers EJ, van Leerdam ME, van Ballegooijen M. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2013; 62: 727-734 [PMID: 22490518 DOI: 10.1136/gutjnl-2011-301917]
50. Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 2012; 10: 633-638 [PMID: 22426085 DOI: 10.1016/j.cgh.2012.02.030]